Welcome!

News Feed Item

Boston Therapeutics Reports Corporate Update and Financial Results for the First Quarter Ended March 31, 2014

MANCHESTER, NH -- (Marketwired) -- 05/13/14 -- Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, reports its financial results for the first quarter ended March 31, 2014.

David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, "In the first quarter, we have continued to work toward fulfilling the milestones we outlined in last quarter's year-end corporate update. Since that time, I am pleased to announce that we have continued to disseminate scientific findings regarding BTI-320, and have initiated steps to prepare for its future development. Specifically, we are pleased to be presenting a poster on the mechanism of action of BTI-320 at the AACE Annual Congress in Las Vegas, and look forward to presenting further results on the properties of this compound in the future. Furthermore, our recently signed agreement with Patheon Inc. to manufacture pharmaceutical-grade tablets of BTI-320 positions us well for our upcoming IND filing later this year, and our planned international Phase III trial for BTI-320 in 2015. All of these efforts will allow us to continue to harness our expertise in complex carbohydrate chemistry to design compounds to better manage blood glucose."

Business and Clinical Highlights for the First Quarter 2014 and Recent Months:

  • Announced the presentation of a late-breaking poster on the mechanism of action for BTI-320 at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific and Clinical Congress at the Paris Las Vegas Hotel in Las Vegas, Nevada. BTI-320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose.

  • Signed agreement (along with the Company's Hong Kong-based strategic partner Advance Pharmaceutical Company) with pharmaceutical manufacturing company Patheon Inc. to manufacture pharmaceutical-grade tablets of BTI-320, in advance of the Company's anticipated IND filing in late 2014 and its planned international Phase III trial for BTI-320 in 2015.

Financial Results for the First Quarter Ended March 31, 2014:

  • Cash and cash equivalents as of March 31, 2014 were $2,512,404 compared with $3,387,428 as of December 31, 2013.

  • Revenue for the first quarter ended March 31, 2014 was $43,827, compared with $23,336 in the prior year's first quarter. Revenue for the quarter was generated from the sale of SUGARDOWN®.

  • Gross margin for the first quarter ended March 31, 2014 was a deficit of ($10,731), compared with a deficit of ($24,601) in the prior year's first quarter. The gross margin deficit for the first quarter ended March 31, 2014 was primarily related to a one-time material cost charge and continued fixed fulfillment charges. The improvement in gross margin is primarily related to the increase in revenue.

  • Research and development expense for the first quarter ended March 31, 2014 was $269,434 compared with $28,661 for the prior year's first quarter. The increase in research and development is primarily the result of expenses associated with Phase II trial activities for BTI-320.

  • Sales and marketing expense for the first quarter ended March 31, 2014 was $172,735, compared with $81,226 in the prior year's quarter. The increase is primarily related to the engagement of a healthcare marketing company to market SUGARDOWN® and the hiring of employees to support our sales and marketing initiatives. Subsequent to the quarter ended March 31, 2014, the Company ended the agreement with the healthcare marketing company and is currently pursuing alternative marketing partners.

  • General and administrative expense for the first quarter ended March 31, 2014 was $1,105,230, an increase of $577,060 as compared to $528,170 for the first quarter ended March 31, 2013. Approximately $313,000 of the increase is related to non-cash, stock-based compensation primarily related to fully vested options granted during the first quarter ended March 31, 2014. Consulting and professional services increased $132,000 primarily due to our business development, public relations and investor relations activities. Accounting, financial and legal professional fees increased $80,000 primarily due to the indemnification of Dr. Platt's legal costs associated with his arbitration and the engagement of a finance professional to manage its accounting and financial reporting matters. In addition, payroll and payroll related expense increased $62,000 due to salary increases, the institution of an employee medical benefit program and the hiring of two new employees.

  • Net loss for the first quarter ended March 31, 2014 was $1,566,423 or $0.04 per share, compared with a net loss of $667,422 or $0.04 per share in the prior year's first quarter. As of March 31, 2014, there were 37,451,156 million weighted average shares outstanding, compared with 18,880,845 million weighted average shares outstanding as of March 31, 2013.

We have incurred recurring operating losses since inception as we have worked to bring our SUGARDOWN® product to market and develop BTI-320 and IPOXYN. IPOXYN is an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. We expect such operating losses will continue until such time that we receive substantial revenues from SUGARDOWN® or we complete the regulatory and clinical development of BTI-320 or IPOXYN. We anticipate that our cash resources will be sufficient to fund our planned operations into the second half of fiscal 2014. We plan to seek additional capital through private placements and public offerings of the Company's common stock. There can be no assurance that the Company will be successful in accomplishing its objectives. Without such additional capital, the Company may be required to curtail or cease operations.

About BTI-320

BTI-320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. BTI-320 is a proprietary polysaccharide to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars, reducing the availability of glucose for absorption into the bloodstream.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320 (formerly PAZ320), a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. The company also produces and sells SUGARDOWN®, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at www.bostonti.com.

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.



                         Boston Therapeutics, Inc.
                    Statement of Operations (Unaudited)

                                                     Three Months Ended
                                                          March 31,
                                                 --------------------------
                                                     2014          2013
                                                 ------------  ------------
Revenue                                          $     43,827  $     23,336
Cost of goods sold                                     54,558        47,937
                                                 ------------  ------------
Gross margin (deficit)                                (10,731)      (24,601)

Operating expenses:
  Research and development                            269,434        28,661
  Sales and marketing                                 172,735        81,226
  General and administrative                        1,105,230       528,170
                                                 ------------  ------------
    Total operating expenses                        1,547,399       638,057
Operating loss                                     (1,558,130)     (662,658)

Interest expense                                       (4,728)       (4,764)
Other expense                                          (2,940)            -
Foreign currency loss                                    (625)            -
                                                 ------------  ------------
    Net loss                                     $ (1,566,423) $   (667,422)
                                                 ============  ============

Net loss per share - basic and diluted           $      (0.04) $      (0.04)
Weighted average shares outstanding basic and
 diluted                                           37,451,156    18,880,845



                          Boston Therapeutics, Inc.
                             Balance Sheet Data

                                                   March 31,    December 31,
                                                      2014          2013
                                                 ------------- -------------

Cash and cash equivalents                        $   2,512,404 $   3,387,428

Working capital                                  $   2,384,994 $   2,859,578

Total assets                                     $   3,469,725 $   4,535,032

Total stockholders' equity                       $   2,857,279 $   3,345,270

© Boston Therapeutics, Inc. All rights reserved.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing be...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
NHK, Japan Broadcasting, will feature the upcoming @ThingsExpo Silicon Valley in a special 'Internet of Things' and smart technology documentary that will be filmed on the expo floor between November 3 to 5, 2015, in Santa Clara. NHK is the sole public TV network in Japan equivalent to the BBC in the UK and the largest in Asia with many award-winning science and technology programs. Japanese TV is producing a documentary about IoT and Smart technology and will be covering @ThingsExpo Silicon Val...
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
While some vendors scramble to create and sell you a fancy solution for monitoring your spanking new Amazon Lambdas, hear how you can do it on the cheap using just built-in Java APIs yourself. By exploiting a little-known fact that Lambdas aren’t exactly single threaded, you can effectively identify hot spots in your serverless code. In his session at 20th Cloud Expo, David Martin, Principal Product Owner at CA Technologies, will give a live demonstration and code walkthrough, showing how to o...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
Developers want to create better apps faster. Static clouds are giving way to scalable systems, with dynamic resource allocation and application monitoring. You won't hear that chant from users on any picket line, but helping developers to create better apps faster is the mission of Lee Atchison, principal cloud architect and advocate at New Relic Inc., based in San Francisco. His singular job is to understand and drive the industry in the areas of cloud architecture, microservices, scalability ...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...